Literature DB >> 16865726

Immunohistochemical characterization of neuroendocrine cells in prostate cancer.

Jiaoti Huang1, Jorge L Yao, P Anthony di Sant'Agnese, Qi Yang, Patricia A Bourne, Yanqun Na.   

Abstract

BACKGROUND: Neuroendocrine (NE) cells increase in high grade/stage prostate cancer (PC) and may contribute to androgen-independent cancer. Their immunohistochemical phenotype has not been studied in detail and conflicting results have been reported.
METHODS: PC tissue was stained immunohistochemically for luminal secretory cell-associated cytokeratin, basal cell markers, ki-67, androgen receptor (AR), PSA, prostate acid phosphatase (PAP), and alpha-methylacyl coenzyme A racemase (AMACR).
RESULTS: The NE cells are positive for AE1/AE3, Cam 5.2, and negative for basal cell markers. They are negative for AR, PSA, and Ki-67 but positive for PAP. The benign NE cells are negative for AMACR while the malignant NE cells are positive for AMACR.
CONCLUSIONS: NE cells of PC constitute a unique subset of cancer cells, which have a unique immunohistochemical profile. They do not express AR, consistent with their resistance to hormonal therapy. They are post-mitotic cells but are malignant and part of the tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16865726     DOI: 10.1002/pros.20434

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  41 in total

1.  Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.

Authors:  Megan Hall; Bryan Todd; Edwin D Allen; Nga Nguyen; Yoon-Jung Kwon; Vu Nguyen; Jennifer L Hearne; Miguel Martin-Caraballo
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Neuroendocrine differentiation of prostate cancer.

Authors:  Zhen Li; Clark J Chen; Jason K Wang; Elaine Hsia; Wei Li; Jill Squires; Yin Sun; Jiaoti Huang
Journal:  Asian J Androl       Date:  2013-03-18       Impact factor: 3.285

3.  Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Authors:  Hongbing Chen; Yin Sun; Chengyu Wu; Clara E Magyar; Xinmin Li; Liang Cheng; Jorge L Yao; Steven Shen; Adeboye O Osunkoya; Chaozhao Liang; Jiaoti Huang
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

Review 4.  Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.

Authors:  Guilhem Roubaud; Bobby C Liaw; William K Oh; David J Mulholland
Journal:  Nat Rev Clin Oncol       Date:  2016-11-22       Impact factor: 66.675

Review 5.  Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.

Authors:  Jiaoti Huang; Jason K Wang; Yin Sun
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

6.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

Review 7.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

8.  Oct4A is expressed by a subpopulation of prostate neuroendocrine cells.

Authors:  Paula Sotomayor; Alejandro Godoy; Gary J Smith; Wendy J Huss
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

9.  Paneth cell-like change in benign prostate can account for P504S (AMACR) reactivity.

Authors:  Kenneth A Iczkowski
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

10.  Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Wendy J Huss; Danny R Gray; Keyvan Tavakoli; Meghan E Marmillion; Lori E Durham; Mac A Johnson; Norman M Greenberg; Gary J Smith
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.